The use of copeptin, the stable peptide of the vasopressin precursor, in the differential diagnosis of sodium imbalance in patients with acute diseases

Swiss Medical Weekly

Volumn 141, Issue OCTOBER, 2011, Pages

  Nigro, Nicole ^a   Müller, Beat ^a,c   Morgenthaler, Nils G ^b   Fluri, Felix ^a   Schuetz, Philipp ^a   Neiderta, Stefanie ^a   Stolz, Daiana ^a   Bingisser, Roland ^a   Tamm, Michael ^a   Christ Crain, Mirjam ^a   Katana, Mira ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b THERMO FISHER SCIENTIFIC   (Germany)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

Acute cerebrovascular event; Community acquired pneumonia; Copeptin; Hypernatraemia; Hyponatraemia; Respiratory tract infections; Vasopressin

Indexed keywords

BIOLOGICAL MARKER; COPEPTIN; PEPTIDE; SODIUM ION; UNCLASSIFIED DRUG; VASOPRESSIN; COPEPTINS; GLYCOPEPTIDE; SODIUM;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CONFIDENCE INTERVAL; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ELECTROLYTE DISTURBANCE; EMERGENCY WARD; FEMALE; HEART FAILURE; HUMAN; HYPERNATREMIA; HYPERVOLEMIA; HYPONATREMIA; KIDNEY FAILURE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PNEUMONIA SEVERITY INDEX; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; STROKE PATIENT; BLOOD; CRITICAL ILLNESS; ELECTROLYTE BALANCE; MIDDLE AGED; SWITZERLAND;

AGED; AGED, 80 AND OVER; CRITICAL ILLNESS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; MIDDLE AGED; SODIUM; SWITZERLAND; WATER-ELECTROLYTE BALANCE;

EID: 80655137766     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2011.13270     Document Type: Article

References (42)

1. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119(7 Suppl 1):S30-5.
2. Rabinstein AA, Wijdicks EF. Hyponatremia in critically ill neurological patients. The neurologist. 2003;9(6):290-300. (Pubitemid 37484848)
3. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356(20):2064-72. (Pubitemid 46789896)
4. Borra SI, Beredo R, Kleinfeld M. Hypernatremia in the aging: causes, manifestations, and outcome. J Natl Med Assoc. 1995;87(3):220-4.
5. Smith DM, McKenna K, Thompson CJ. Hyponatraemia. Clin Endocrinol. 2000;52(6):667-78. (Pubitemid 30409257)
6. Reynolds RM, Seckl JR. Hyponatraemia for the clinical endocrinologist. Clin Endocrinol. 2005;63(4):366-74. (Pubitemid 41442330)
7. Patel GP, Balk RA. Recognition and treatment of hyponatremia in acutely ill hospitalized patients. Clin Ther. 2007;29(2):211-29. (Pubitemid 46654223)
8. Musch W, Thimpont J, Vandervelde D, Verhaeverbeke I, Berghmans T, Decaux G. Combined fractional excretion of sodium and urea better predicts response to saline in hyponatremia than do usual clinical and biochemical parameters. Am J Med. 1995;99(4):348-55.
9. Chung HM, Kluge R, Schrier RW, Anderson RJ. Clinical assessment of extracellular fluid volume in hyponatremia. Am J Med. 1987;83(5):905-8. (Pubitemid 18098166)
10. Hoorn EJ, Halperin ML, Zietse R. Diagnostic approach to a patient with hyponatraemia: traditional versus physiology-based options. Qjm. 2005;98(7):529-40. (Pubitemid 41418674)
11. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(11 Suppl 1):S1-21.
12. Ball SGs Vasopressin and disorders of water balance: the physiology and pathophysiology of vasopressin. Ann Clin Biochem. 2007;44(Pt 5):417-31.
13. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock (Augusta, Ga. 2007;28(2):219-26.
14. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides. 2005;26(12):2500-4. (Pubitemid 41676723)
15. Jochberger S, Morgenthaler NG, Mayr VD, Luckner G, Wenzel V, Ulmer H, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab. 2006;91(11):4381-6. (Pubitemid 44833413)
16. Szinnai G, Morgenthaler NG, Berneis K, Struck J, Muller B, Keller U, et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab. 2007;92(10):3973-8. (Pubitemid 47607649)
17. Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: clinical use of a new biomarker. Trends in endocrinology and metabolism: TEM. 2008;19(2):43-9. (Pubitemid 351317895)
18. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112-9. (Pubitemid 43032474)
19. Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2008 Nov 4.
20. Mueller C, Muller B, Perruchoud AP. Biomarkers: past, present, and future. Swiss Med Wkly. 2008;138(15-16):225-9. (Pubitemid 351579079)
21. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600-7. (Pubitemid 38264177)
22. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia: A Randomized Trial. Am J Respir Crit Care Med. 2006;174(1):84-93. (Pubitemid 43955248)
23. Muller B, Morgenthaler N, Stolz D, Schuetz P, Muller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest. 2007;37(2):145-52. (Pubitemid 46066494)
24. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-50. (Pubitemid 27044625)
25. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009;66(6):799-808.
26. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke; a journal of cerebral circulation. 1989;20(7):864-70. (Pubitemid 19188240)
27. Verbalis JG. Disorders of body water homeostasis. Best practice & research. 2003;17(4):471-503.
28. Miller M. Hyponatremia and arginine vasopressin dysregulation: mechanisms, clinical consequences, and management. J Am Geriatr Soc. 2006;54(2):345-53.
29. Kumar S, Berl T. Sodium. Lancet. 1998;352(9123):220-8. (Pubitemid 28329332)
30. Reynolds RM, Padfield PL, Seckl JR. Disorders of sodium balance. BMJ (Clinical research ed. 2006;332(7543):702-5.
31. Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. 1957. J Am Soc Nephrol. 2001;12(12):2860-70.
32. Adrogue HJ, Madias NE. Hypernatremia. N Engl J Med. 2000;342(20):1493-9. (Pubitemid 30318274)
33. Sweeney TE, Beuchat CA. Limitations of methods of osmometry: measuring the osmolality of biological fluids. Am J Physiol. 1993;264(3 Pt 2):R469-80. (Pubitemid 23109894)
34. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342(21):1581-9. (Pubitemid 30340505)
35. Thompson SG, Turner RM, Warn DE. Multilevel models for meta-analysis, and their application to absolute risk differences. Stat Methods Med Res. 2001;10(6):375-92. (Pubitemid 33103814)
36. Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med. 2000;19(24):3417-32. (Pubitemid 32056694)
37. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009;116(3):257-63.
38. Lightman SL. The neuroendocrinology of stress: a never ending story. J Neuroendocrinol. 2008;20(6):880-4. (Pubitemid 351858741)
39. Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro endocrinology letters. 2008;29(3):341-6.
40. Kelly D, Squire IB, Khan SQ, Quinn P, Struck J, Morgenthaler NG, et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Cardiac Fail. 2008;14(9):739-45.
41. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007;115(16):2103-10. (Pubitemid 46659061)
42. Chikanza IC, Petrou P, Chrousos G. Perturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implications. Ann N Y Acad Sci. 2000;917:825-34.